Myeloma
164
22
33
76
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
37 trials with published results (23%)
Research Maturity
76 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.0%
23 terminated out of 164 trials
76.8%
-9.7% vs benchmark
5%
8 trials in Phase 3/4
49%
37 of 76 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 76 completed trials
Clinical Trials (164)
Evaluation of Skin Tests in Biotherapy Allergies
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Pilot Imaging Study of Leukemia
REal World MAIA UK OutcomEs
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Removing Transfusion Dependence as a Barrier to Hospice Enrollment
Non-invasive MRD Assessment in Multiple Myeloma